drugset
drugset / Trial / NCT04341857

PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma

NCT04341857 ↗

Phase 2 Unknown 25 enrolled Henan Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective single arm phase II clinical study to compare the safety and efficacy of PD-1monoclonal antibody +FLOT in patients with gastric adenocarcinoma/esophagus-gastric junction adenocarcinoma.

Timeline

Start
2019-07-30
Primary completion
2022-05-30
Completion
2022-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Sintilimab Monoclonal antibody 200 mg Intravenous
Background Calcium leucovate Unknown 200 mg/m2 Intravenous
Background Docetaxel Small molecule 50 mg/m2 Intravenous
Background Oxaliplatin Small molecule 80 mg/m2 Intravenous
Background fluorouracil Small molecule 2600 mg/m2 Intravenous

Indications

gastroesophageal adenocarcinoma